Abstract: Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.

Abstract: The present invention is directed to a flowable mixture including: a) a hydrated clay suspension and b) sulfur derived from elemental sulfur. Preferably, the flowable mixture includes elemental sulfur particles and a hydrated, absorbent clay, such as bentonite clay. The flowable mixture is preferably a liquid mixture for use as a fertilizer or fungicide.

Abstract: The subject invention provides a solid unit dosage form comprising pridopidine or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form has a volume and wherein the ratio of the amount of pridopidine to the volume of the dosage form is 135-600 mg/ml.

Abstract: A transdermal delivery composition for the delivery to skin and the penetration of the skin includes: (a) a therapeutic effective amount of a cannabinoid mixture, wherein the cannabinoid mixture comprises cannabidiol (CBD) and ?9-tetrahydrocannabinol (THC) at a weight ratio of about 1:20 to about 20:1; (b) a hydrophilic polymer/hydrophobic polymer adduct in an amount sufficient to hold the cannabinoid composition and provide a sustain release of the cannabinoid mixture after application to skin tissue over a time period of at least 6 hours; (c) a penetrant component in an amount sufficient to assist with a transdermal penetration of the cannabinoid mixture through skin tissue once the composition has been applied to skin tissue; (d) a surfactant component in an amount sufficient to stabilize the polymer adduct and release the cannabinoid mixture from the transdermal delivery composition upon application to skin tissue; and (e) at least about 70 wt. % water.

Abstract: The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides. Such compositions serve the dual purpose of preventing pregnancy and lessening the risk of spreading sexually transmitted diseases. More specifically, the compositions and methods relate to synergistic contraceptive microbicide and antiviral compositions comprising a combination of a contraceptive microbicide and an antiviral agent in an acidic carrier that enhances the efficacy of both the contraceptive microbicide and antiviral agent.

Abstract: Disclosed is use of a compound of the formula (I) to increase the amount of melanin in melanocytes, where: R1 is formula (AA) in which, X is H, CH3, (CH2)n—CH3 or a substituted alkyl group, Y is H, CH3, (CH2)n—CH3 or a substituted alkyl group and Z is H or OH; and R2 is H, OH, NH2 or —O—(OH2)n? where, n=1 to 3 and ? is phenyl, naphthyl or alkyl group further optionally substituted with halogen, aryl or NH2 group, where compound of formula 1 is not a compound in which X is H, Y is CH3 and Z is OH.

Abstract: Stable and bioavailable oral dosage forms of ibrutinib, the dosage forms comprising ibrutinib and an acidifying agent. The dosage forms can further comprise a binder, such as sodium alginate, a surfactant, a lubricant, a filler and/or a disintegrant. Methods of treating cancers, particularly blood cancers, and graft versus host disease comprising administering to a patient in need thereof a dosage form comprising ibrutinib and an acidifying agent.

Abstract: Materials and methods for reducing, preventing, or mitigating the effects of exposure to ionizing radiation are provided herein. In general, the methods can include administering a nanoparticulate genistein composition to a subject identified as having been exposed or at risk of being exposed to ionizing radiation, such as proton radiation.

Abstract: The invention relates to resorcinol-based compounds of formula (I), to the salts, solvates, optical and/or geometrical isomers thereof, to the use thereof as active agents for depigmenting, lightening and/or bleaching keratin materials, and/or for preventing, reducing and/or treating impairment of the skin complexion or of the colour of the semi-mucous membranes. The invention also relates to a non-therapeutic cosmetic treatment process for depigmenting, lightening and/or bleaching keratin materials, and/or for preventing, reducing and/or treating impairment of the skin complexion or the colour of the semi-mucous membranes.

Abstract: The invention provides, in the field of caring for and/or making up keratin materials, especially the skin, a composition in water-in-oil emulsion form, containing: a) a continuous oily phase, b) a discontinuous aqueous phase dispersed in the oily phase; c) at least baicalin and/or a derivative thereof and/or a plant extract containing the compound(s); d) at least one vitamin B3 and/or a derivative thereof; e) at least one xanthine base and/or a plant extract containing same; and f) at least one polyvalent cation salt.

Abstract: The present invention relates to a technology for producing a black pearlescent pigment for cosmetics which is a human-friendly and nature-friendly by using a pigment including natural charcoal powder. The production method of the pearlescent pigment using natural charcoal according to the present invention includes (a) milling natural charcoal to produce a pigment including natural charcoal powder; and (b) coating a flake substrate with the produced pigment including the natural charcoal powder, wherein the milling is performed at 20 to 40 Hz for 24 to 72 hours, and an average particle size of the pigment including the natural charcoal powder is 100 to 300 nm.

Abstract: The invention relates to self-assembled nanofibers of chitosan and bioactive compounds for use as nutraceuticals or drugs. Suitable bioactive compounds include molecules of a low molecular size with acid or lactone groups, aromatic rings and hydroxyls. The nanofibers are absorbed, without degradation, in the small intestine, containing and protecting the bioactive compounds until they reach target organs. The nanofibers also cross the blood-brain barrier, allowing the compounds to reach the brain where they act as a controlled release system. If the bioactive compounds are neuroprotectors, the nanofibers can treat or prevent neurodegenerative diseases, strokes and other diseases related to aging or associated with oxidative stress. The invention also relates to a method for obtaining the nanofibers involving mixing chitosan with the bioactive compounds and allowing self-assembly. The invention further relates to a dosage form containing the nanofibers, particularly for oral administration.

Abstract: Described are implantable pouch products having a segmental lamination structure that provides an interior pocket for receiving a medical device, for example an electronic medical device such as a cardiac pacemaker or defibrillator. Also described are methods for making and using such products.

Abstract: The present invention relates to a nicotine delivery product comprising, or even consisting essentially of, a population of nicotine-loaded cation exchange resin particles, said population comprises at least 50% (w/w) particles having a size in the range of 90-300 micron which provides an improved nicotine stability to oral dosage forms comprising the nicotine delivery product. The invention furthermore relates to methods of producing the nicotine delivery product and the oral dosage forms and to the use of the nicotine delivery product.

Abstract: A method for the preparation of a composition includes dispersing particulate pimobendan in a molten carrier matrix to form particles coated with the carrier matrix, where the molten carrier matrix includes one or more pharmaceutically acceptable carriers selected from a polyglycolized glyceride, a polyethylene glycol, and combinations thereof, atomizing the dispersion of coated particles, and cooling and collecting the coated particles from the atomized dispersion.

Abstract: Described herein are loaded nanoparticles of Sorafenib (Sorafenib PBB) or Sorafenib derivatives (Sorafenib PBB derivatives), wherein the nanoparticles are polymeric PBB nanoparticles, (PHEA-BIB-pButMA, ?,?-poly(N-2-hydroxyethyl)-co-{N-2-ethylene-[2-(poly(butylmethacrylate)-isobutyrate]}-D, L-aspartamide, as well as a method for obtaining them. Also described herein are a controlled release formulation of Sorafenib or Sorafenib, derivatives that include Sorafenib PBB or Sorafenib PBB derivatives, and to the use of the formulation in the treatment of tumor diseases of the kidney, liver, thyroid, colon, breast, pancreas, lungs and/or recurrent glioblastoma.

Abstract: The present invention relates to a medical solution. According to the invention the ready-for-use solution comprises phosphate in a concentration of 1.0-2.8 mM, is sterile and has a pH of 6.5-7.6. The present invention further relates to a method for producing the medical solution and the use thereof.

Abstract: Provision of a material, which has activity of inhibiting endothelin-converting enzyme and is effective for skin whitening or antihypertension. An endothelin-converting enzyme inhibitor comprising, as an active ingredient, at least one selected from the group consisting of Hiptage candicans, Piper sarmentosum, Solanum stramonifolium, Anaxagorea luzonensis, Smilax corbularia, Ardisia elliptica, Erythrina suberosa, Dactyloctenium aegyptium, Hopea ferrea and extracts thereof.

Abstract: A subject matter of the present invention is the cosmetic use of at least one compound of formula (I): in which: (II) denotes a divalent radical chosen from a carbon-carbon single bond *—CH2—CH2—* or double bond *—CH?CH—*, of Z or E configuration or their mixtures, b=0 or 1, c=0 or 1, d=0, 1 or 2, and R and R? independently denote a hydrogen atom, a linear C1-C6 alkyl radical or a branched C3-C6 alkyl radical, to treat and/or prevent signs of aging and/or of photoaging of keratinous substances, preferably of the skin, and/or to depigment, lighten and/or whiten keratinous substances, preferably the skin. The present invention also relates to novel compounds and to a corresponding cosmetic method.

Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.